Fc Variant Hinge Engineering for Antibody Effector Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibody therapies for cancer and autoimmune diseases have suboptimal potency in mediating cytotoxic effector functions such as ADCC and CDC, and there is a need to enhance or reduce FcγR-mediated effector functions depending on the therapeutic goal, while maintaining stability and interaction with other important Fc ligands.
Innovation Solution
Development of Fc variants with modified hinge regions that alter binding affinity to Fc ligands like FcγRs and C1q, and modulate effector functions by introducing amino acid insertions, deletions, substitutions, or rearrangements, allowing for enhanced or reduced ADCC and CDC activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antibody therapies are used, then they can treat cancer and autoimmune diseases, but their potency in mediating cytotoxic effector functions (ADCC and CDC) is suboptimal
Solution Approach 1:
The patent applies parameter changes by modifying the hinge domain amino acid sequence of the Fc region. Specific substitutions (e.g., L231A, S232A, T234A, N297Q) and deletions (e.g., Δ219-223, Δ226-230) are introduced to alter the binding affinity to FcγRs and C1q, thereby enhancing ADCC and CDC potencies while maintaining therapeutic efficacy
Solution Approach 2:
The patent applies local quality by making targeted modifications specifically in the hinge domain region of the Fc region, rather than altering the entire antibody structure. This localized engineering allows selective enhancement of effector function binding while preserving other important Fc ligand interactions and overall antibody stability
2Productivity
If Fc variants with modified hinge regions are developed to enhance effector functions, then ADCC and CDC activities are improved, but the complexity of antibody engineering increases
Solution Approach 1:
The patent applies segmentation by dividing the Fc region into functional domains and specifically targeting the hinge domain for modification. By focusing engineering efforts on this specific segment rather than the entire antibody, the complexity is managed while achieving the desired enhancement in effector functions
Solution Approach 2:
The patent applies dynamics by creating a platform of Fc variants with different hinge domain configurations that can be dynamically selected and optimized for specific therapeutic indications. Multiple variant options (with different substitution and deletion combinations) provide flexibility to match specific clinical needs without requiring complete redesign
3Adaptability or versatility
If hinge domain modifications are introduced to alter binding affinity to Fc ligands, then effector functions are modulated, but stability and interaction with other Fc ligands may be compromised
Solution Approach 1:
The patent applies parameter changes by systematically varying specific amino acid positions in the hinge domain to fine-tune binding affinity parameters. The modifications are designed to selectively enhance affinity for activating FcγRs (like FcγRIIIA) and C1q while maintaining appropriate interactions with other Fc ligands through careful selection of substitution and deletion patterns
Solution Approach 2:
The patent applies feedback by using binding affinity data and effector function measurements to guide further hinge domain optimization. The iterative process of modifying, testing, and refining the hinge variants ensures that stability and ligand interactions are maintained while achieving enhanced effector functions
Data Source
AI summary
The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., FcγRs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more FcγR and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.